# NRX Pharmaceuticals, Inc. Common Stock (NRXP)

> NRX Pharmaceuticals, Inc. Common Stock (NRXP) trades at $2.15 (-15.70%) as of 7:58:20 PM EST on Nov 20, 2026, -10.42% over the past month. Market cap is $95.31M, with 4.6 days to cover in short interest.

Canonical: https://massive.com/quote/nrxp
Data as of: 2026-11-21T00:58:20.243Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.15** -0.40 (-15.70%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$2.23** +0.08 (+3.69%)
As of 7:58:20 PM EST on Nov 20, 2026 · After hours

## Stock performance

How NRX Pharmaceuticals, Inc. Common Stock (NRXP) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -15.69% |
| 1W | -1.83% |
| 1M | -10.42% |
| YTD | -20.66% |
| 1Y | -4.02% |
| 52-wk range | $1.62 – $5.06 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for NRXP: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.14 – $2.53 |
| Open | $2.53 |
| Prev close | $2.55 |
| Volume | 1.48M |
| Market cap | $95.31M |
| Shares out | 43.65M |

## Valuation and profitability ratios

Valuation and profitability ratios for NRX Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 22.11 |
| P/B | -47.99 |
| P/FCF | — |
| ROE | 995.2% |
| ROA | -71.1% |
| Debt/Equity | -0.13 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[NRX Pharmaceuticals, Inc. Common Stock (NRXP) insider trading](https://massive.com/quote/nrxp/insider-trading.md): open-market Form 4 buys and sells by NRX Pharmaceuticals, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events NRX Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 2, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On October 30, 2026, NRx Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Preservative-Free Ketamine, ahead of the November 10, 2026 goal date established under the Generic Drug User Fee Amendments ("GDUFA").”
- Oct 16, 2026 · Shareholder meeting notice
  “On October 16, 2026, the board of directors (the "Board") of NRx Pharmaceuticals, Inc. (the "Company") established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") and set October 28, 2026 as the record date for determining stockholders entitled to vote at the 2026 Annual Meeting. The 2026 Annual Meeting will be held at 10:00 a.m., Eastern Time, in a virtual-only format conducted by live webcast.”
- Oct 5, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “The clinical trial has been approved by the U.S. Food and Drug Administration and is expected to begin enrolling patients.”
- Sep 16, 2026 · [Regulatory decision](https://massive.com/quote/sec-filings/8-k/regulatory-decisions.md)
  “On September 15, 2026, NRx Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the Company that the amendment to its Abbreviated New Drug Application (ANDA), previously classified as a Major Amendment, has been reclassified as a Minor Amendment.”
- Sep 14, 2026 · Investor presentation
  “On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the "Company") used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors and other persons. The Company may continue to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and other persons.”

## Dividend history and stock splits

NRX Pharmaceuticals, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-10 · Apr 2, 2024

## NRXP short interest

How heavily NRXP is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.6 |
| Short interest | 10.46M |
| Avg volume | 2.29M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## NRXP news

The latest news and headlines about NRX Pharmaceuticals, Inc. Common Stock (NRXP).

- [NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates](https://www.zacks.com/stock/news/3030732/nrx-pharmaceuticals-inc-nrxp-reports-q3-loss-misses-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3030732) · Zacks Investment Research · Nov 16, 2026 · negative sentiment
- [NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage](https://www.globenewswire.com/news-release/2026/11/11/3400572/0/en/nrx-pharmaceuticals-begins-selling-u-s-made-preservative-free-ketamine-amid-long-running-shortage.html) · GlobeNewswire Inc. · Nov 11, 2026 · positive sentiment
- [Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag Estimates](https://www.zacks.com/stock/news/3017975/shionogi-co-ltd-unsponsored-adr-sgioy-q2-earnings-lag-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3017975) · Zacks Investment Research · Oct 29, 2026 · neutral sentiment
- [NRx Pharmaceuticals to Participate in Upcoming Investor Conferences](https://www.globenewswire.com/news-release/2026/09/08/3357470/0/en/nrx-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html) · GlobeNewswire Inc. · Sep 8, 2026 · positive sentiment
- [NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock](https://www.benzinga.com/pressreleases/26/06/g52966680/nrx-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Jun 3, 2026 · neutral sentiment

## About NRX Pharmaceuticals, Inc. Common Stock

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Listed | May 25, 2021 |

[Company website](https://nrxpharma.com)

## FAQ

### What is the NRX Pharmaceuticals, Inc. Common Stock (NRXP) stock price today?

NRX Pharmaceuticals, Inc. Common Stock (NRXP) is trading at $2.15 (-15.70% on the day) as of 7:58:20 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is NRX Pharmaceuticals, Inc. Common Stock?

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

### What is the short interest in NRXP?

As of Oct 30, 2026, NRXP has 10.46M shares short and 4.6 days to cover.

### What exchange is NRXP listed on?

NRX Pharmaceuticals, Inc. Common Stock (NRXP) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time NRXP quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=NRXP`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [NRX Pharmaceuticals, Inc. Common Stock (NRXP) insider trading](https://massive.com/quote/nrxp/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
